Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 11:12:963753.
doi: 10.3389/fonc.2022.963753. eCollection 2022.

Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials

Matthew Ledenko  1 , Samuel O Antwi  2 , Shiho Arima  3 , Julia Driscoll  1 , Junji Furuse  4 , Heinz-Josef Klümpen  5 , Finn Ole Larsen  6 , David K Lau  7   8 , Annett Maderer  9   10 , Alice Markussen  6 , Markus Moehler  9   10 , Lynn E Nooijen  11 , Walid L Shaib  12 , Niall C Tebbutt  13 , Thierry André  14 , Makoto Ueno  15 , Rachel Woodford  16 , Changhoon Yoo  17 , Mark M Zalupski  18 , Tushar Patel  1
Affiliations

Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials

Matthew Ledenko et al. Front Oncol. .
No abstract available

Keywords: Biliary cancers; chemotherapy; gemcitabine; survival; therapeutic response.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Identification of studies. Flowchart of the systematic search to identify studies and selection of studies included in the analysis.
Figure 2
Figure 2
Comparison of median overall survival (OS) in female and male participants in treatment trials of cholangiocarcinoma. (A) Data were obtained from participants in 19 treatment groups from 15 studies. Treatment groups above the dotted line of equivalence have a higher overall survival in females compared with males. (B) The ratio of median OS in females to median OS in males is plotted for each treatment group. Treatments with higher median OS in females are plotted above the dotted line, with ratio >1. Randomized of treatment was performed in studies represented by solid dots, non-randomized studies as open dots.
Figure 3
Figure 3
Comparison of disease progression in female and male participants in treatment trials of cholangiocarcinoma. (A) Data were obtained from participants in 19 treatment groups from 15 studies. Treatment groups above the dotted line of equivalence have a higher median progression free survival (mPFS) in females compared with males. (B) The ratio of mPFS in females to mPFS in male is plotted for each treatment group. Treatments with higher mPFS in females are plotted above the dotted line, with ratio >1. Randomized of treatment was performed in studies represented by solid dots, non-randomized studies as open dots.
Figure 4
Figure 4
Relationship between study size, median overall survival (mOS) and median progression-free survival (mPFS) in males and female participants of treatment trials in cholangiocarcinoma. The female-to-male ratio of mOS is plotted against the female-to-male ratio of mPFS. The size of the plot is proportional to the number of participants in the treatment group.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A, et al. . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2018) 68(6):394–424. doi: 10.3322/caac.21492 - DOI - PubMed
    1. Huang YK, Wang M, Sun YDi, Costanzo N, Mitchell C, Achuthan A, et al. . Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry. Nat Commun (2019) 10(1):3928. doi: 10.1038/s41467-019-11788-4 - DOI - PMC - PubMed
    1. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet (2016) 388(10060):2654–64. doi: 10.1016/S0140-6736(16)30354-3 - DOI - PubMed
    1. Zhang M, Hu S, Min M, Ni Y, Lu Z, Sun X, et al. . Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing. Gut (2020). doi: 10.1136/gutjnl-2019-320368 - DOI - PMC - PubMed
    1. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. . Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol (2016) 17(7):956–65. doi: 10.1016/S1470-2045(16)30066-3 - DOI - PubMed

Publication types

LinkOut - more resources